YOLFTbeta
Suzhou Fushilai Pharmaceutical Co. Ltd.

Suzhou Fushilai Pharmaceutical Co. Ltd.

301258 · SHE · Healthcare / Biotechnology

22.90CNY-0.56 (-2.39%)

Price History

Full chart

Market Stats

Previous Close23.46
Open23.46
Day Range22.68 – 23.70
52-Week Range21.78 – 38.00
Volume780.40K
Market Cap2.51B
P/E (TTM)391.43
Forward P/E0.00
EPS0.07
Dividend Yield0.80%
Beta0.38
50-Day Avg25.46
200-Day Avg29.39

About

Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; L-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonsteroidal anti-inflammatory analgesic used to relieve the pain symptoms of osteoarthritis. Its products are used in medicines, dietary supplements, and cosmetics applications. The company also engages in research and experimental development and capital market activities. Suzhou Fushilai Pharmaceutical Co., Ltd. was founded in 2000 and is based in Changshu, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Xiangyun Qian
  • Employees540
  • HeadquartersNo.16 Haiwang Road, Changshu, China, 215500, China
  • Websitehttps://www.fuslai.com

Leadership

  • Mr. Xiangyun QianChairman & GM · b. 1969
  • Mr. Aijin BianDeputy GM, Board Secretary, Financial Director, Head of Accounting Agency & Director · b. 1985

Financials

Income Statement

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue452.50M476.85M521.70M568.21M489.29M429.47M432.73M
Growth (%)-+5.38%+9.40%+8.92%-13.89%-12.23%+0.76%
Cost of Revenue226.96M251.46M311.51M311.18M301.38M345.17M360.52M
Gross Profit225.54M225.39M210.18M257.03M187.91M84.30M72.21M
Gross Margin49.84%47.27%40.29%45.24%38.40%19.63%16.69%
Operating Expense57.59M57.50M65.49M85.71M91.69M85.53M80.31M
Operating Income167.95M167.90M144.69M171.32M96.22M-1.23M-8.10M
Operating Margin37.12%35.21%27.74%30.15%19.67%-0.29%-1.87%
EBITDA186.63M181.21M185.45M254.64M185.31M67.35M122.92M
EBITDA Margin41.24%38.00%35.55%44.81%37.87%15.68%28.41%
Net Income145.71M141.05M120.20M177.31M112.18M16.41M64.29M
Net Income Margin32.20%29.58%23.04%31.20%22.93%3.82%14.86%
R&D18.39M22.88M28.51M41.37M40.70M40.62M35.80M
R&D as % of Total Revenue4.06%4.80%5.47%7.28%8.32%9.46%8.27%
Interest Expense7.25K-450.04K307.22K116.46K90.91K63.81K
Interest Expense % of Total Revenue0.00%-0.09%0.05%0.02%0.02%0.01%

Balance Sheet

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets751.44M788.25M970.31M2.10B2.12B2.09B2.12B
Total Liabilities169.48M165.61M227.47M211.75M170.45M200.84M255.33M
Total Equity581.96M622.64M742.84M1.89B1.95B1.89B1.86B
Cash194.91M98.09M332.06M259.69M349.74M224.73M361.68M

Cash Flow

Currency: CNY2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow150.55M166.85M199.73M151.19M94.77M47.07M66.60M
Capital Expenditure70.93M65.69M80.75M50.11M41.62M105.31M146.50M
Free Cash Flow79.62M101.16M118.98M101.08M53.15M-58.25M-79.90M
Dividends Paid49.51M100.38M436.30K36.93M53.17M54.98M8.26M
FCF to OCF52.89%60.63%59.57%66.86%56.08%-123.75%-119.96%
Dividend Paid to FCF62.18%99.23%0.37%36.54%100.04%-94.39%-10.34%

Earnings

Report DateMar 31, 2022Jun 30, 2022Sep 30, 2022Dec 31, 2022Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate------------------
EPS Actual0.440.550.410.550.560.490.120.050.06-0.070.160.030.260.210.34-0.10-0.03-0.13
Surprise------------------
Timing------------------

Key Statistics & Ratios

Market Cap2.51B
Enterprise Value1.33B
Trailing P/E391.43
Forward P/E0.00
Price / Sales6.37
Price / Book1.35
EPS0.07
Book Value20.66
Revenue (TTM)394.29M
Gross Profit (TTM)55.93M
EBITDA14.24M
Profit Margin1.67%
Operating Margin-14.98%
Return on Equity0.35%
Return on Assets-0.99%
Shares Outstanding91.67M
Shares Float30.74M
Beta0.38
Dividend Yield0.80%
Dividend Rate0.22
Payout Ratio3.13%

Dividends

20261×
0.22May 29, 2026
20251×
0.09Jun 12, 2025
20241×
0.60Jun 12, 2024
20231×
0.58Jun 8, 2023
20221×
0.40Jun 8, 2022